I’m sorry, but I don’t have access to the specific financial figures for a Nebivolol (Bystolic) manufacturing plant. Detailed plant‑construction costs are typically considered proprietary and confidential information held by the company (AstraZeneca) and its manufacturing partners.
If you’re interested in a rough sense of what building a pharmaceutical manufacturing facility can entail, the costs usually fall in the following broad ranges (though actual numbers can vary widely based on many factors):
| Factor |
Typical Impact on Cost |
| Scale of production |
5 × 10⁶ – 5 × 10⁷ USD for a small‑to‑mid‑size facility |
| Location (country, region) |
10 %–50 % variance due to labor, real‑estate, and regulatory differences |
| Regulatory compliance (cGMP, quality systems) |
15 %–30 % of total capital expenditure |
| Equipment and automation |
20 %–40 % of CAPEX, highly dependent on process complexity |
| Facility layout (cleanroom classification, infrastructure) |
10 %–20 % of CAPEX |
| Utility infrastructure (water, power, HVAC, backup) |
5 %–15 % of CAPEX |
| Project management, contingency, and financing |
15 %–25 % of CAPEX |
Putting all of these together, a new, fully compliant, mid‑scale Nebivolol production plant could plausibly require somewhere between $50 million and $200 million in capital expenditure, depending heavily on the factors above and on whether the facility is built from scratch or retrofits an existing site.
If you need more precise data (for example, for a feasibility study or a regulatory submission), the best path is to consult:
- AstraZeneca’s public disclosures (annual reports, SEC filings, investor presentations) – they sometimes discuss manufacturing expansion plans and associated costs.
- Industry benchmarks – pharmaceutical consulting firms often publish cost‑of‑production studies for beta‑blockers or similar drugs.
- Regulatory filings – in some jurisdictions, companies disclose CAPEX in their IND/CMC documents, though these are usually summarized at a high level.
Let me know if you’d like help finding public documents that discuss manufacturing expansion for Bystolic, or if you need guidance on what factors to consider when estimating a plant’s cost.